- Cancer and autoimmune disease focused Tiziana Life Sciences posted a first-half loss as it continued to invest in research and development.

Net losses for the six months through June amounted to £3.9m, in line with a loss of £3.9m on-year.

The company had £0.1m cash as at 30 June and said it would continue to seek to raise funds through the issue of American depository shares.

'It has been a busy six months for the company as we have bolstered our senior leadership team and scientific advisory board, and continued to progress our pipeline of drugs to treat rare cancers and difficult to treat autoimmune inflammatory diseases,' executive chairman Gabriele Cerrone said.

'Looking forward, we are confident of being well positioned to progress these programmes to their next respective value inflection points.'

At 1:42pm: [LON:TILS] Tiziana Life Sciences Plc share price was +6.5p at 116p

Story provided by